Beta-Blockers in Asymptomatic Coronary Artery Disease No Benefit or No Evidence?

被引：11
|
作者：
Steg, Philippe Gabriel [1 ,2 ,3 ,4 ]
De Silva, Ranil [4 ,5 ]
机构：
[1] Hop Bichat Claude Bernard, AP HP, Dept Hosp Univ FIRE, F-75018 Paris, France
[2] Univ Paris Diderot, Paris, France
[3] INSERM, U 1148, Paris, France
[4] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England
[5] Royal Brompton & Harefield NHS Fdn Trust, NIHR, Cardiovasc Biomed Res Unit, London, England
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 64卷 / 03期
关键词：
beta-blockers; coronary artery disease; ACUTE MYOCARDIAL-INFARCTION; CLINICAL-OUTCOMES; CARDIOVASCULAR EVENTS; HEART; CARVEDILOL; METOPROLOL; MORTALITY; THERAPY; OUTPATIENTS; MANAGEMENT;
D O I：
10.1016/j.jacc.2014.04.043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：253 / 255
页数：3
相关论文
共 50 条
  • [31] Beta-blockers in the prevention and treatment of ischemic heart disease: Evidence and clinical practice
    Khan, Omer
    Patel, Murti
    Tomdio, Anna N.
    Beall, Jeffrey
    Jovin, Ion S.
    HEART VIEWS, 2023, 24 (01): : 41 - 49
  • [32] Poor adherence to beta-blockers is associated with increased long-term mortality even beyond the first year after an acute coronary syndrome event
    Allonen, Jaakko
    Nieminen, Markku S.
    Sinisalo, Juha
    ANNALS OF MEDICINE, 2020, 52 (3-4) : 74 - 84
  • [33] Role of Beta-blockers in Cardiovascular Disease in 2019
    Martinez-Milla, Juan
    Raposeiras-Roubin, Sergio
    Pascual-Figal, Domingo A.
    Ibanez, Borja
    REVISTA ESPANOLA DE CARDIOLOGIA, 2019, 72 (10): : 844 - 852
  • [34] The role of beta-blockers in the management of chronic obstructive pulmonary disease
    Leitao Filho, Fernando Sergio
    Alotaibi, Nawaf M.
    Yamasaki, Kei
    Ngan, David A.
    Sin, Don D.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (02) : 125 - 135
  • [35] Asymptomatic hyperuricaemia and coronary artery disease
    Miranda-Aquino, Tomas
    Esmeralda Perez-Topete, Silvia
    Gonzalez-Padilla, Christian
    Eduardo Hernandez-del Rio, Jorge
    Sergio Lomeli-Sanchez, Oscar
    Miguel Esturau-Santalo, Ramon
    Ramon Gutierrez-Urena, Sergio
    Gonzalez-Diaz, Veronica
    REUMATOLOGIA CLINICA, 2021, 17 (05): : 263 - 267
  • [36] Are Tolerability Concerns a Class Effect of Beta-Blockers in Treating Patients with Hypertension?
    Kountz, David S.
    POSTGRADUATE MEDICINE, 2009, 121 (01) : 14 - 24
  • [37] What is the role of beta-blockers in a contemporary treatment cohort of patients with acute coronary syndrome? A propensity-score matching analysis
    Timoteo, Ana Teresa
    Rosa, Silvia Aguiar
    Cruz, Madalena
    Moreira, Rita Ilhao
    Carvalho, Ramiro
    Ferreira, Maria Lurdes
    Ferreira, Rui Cruz
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2018, 37 (11) : 901 - 908
  • [38] Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease
    Gjin Ndrepepa
    Siegmund Braun
    Albert Schömig
    Adnan Kastrati
    Clinical Research in Cardiology, 2011, 100 : 327 - 333
  • [39] Beta-blockers for hypertension
    Wiysonge, Charles Shey
    Bradley, Hazel A.
    Volmink, Jimmy
    Mayosi, Bongani M.
    Mbewu, Anthony
    Opie, Lionel H.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (08):
  • [40] The vasodilatory beta-blockers
    Michala E. Pedersen
    John R. Cockcroft
    Current Hypertension Reports, 2007, 9 : 269 - 277
12345